Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety, and Tolerability of Switching to a Two-Drug Regimen With DTG/3TC Compared to Maintaining a Three-Drug Regimen With BIC/FTC/TAF or DTG/3TC/ABC in Virologically Suppressed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

NCT07138144 is registered in ClinicalTrials.gov with José Antonio Mata Marín as lead sponsor.

NCT NCT07138144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07138144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety, and Tolerability of Switching to a Two-Drug Regimen With DTG/3TC Compared to Maintaining a Three-Drug Regimen With BIC/FTC/TAF or DTG/3TC/ABC in Virologically Suppressed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up
Lead sponsor
José Antonio Mata Marín
Phase
Phase 4
Overall status
Recruiting
Start date
July 12, 2025
Completion date
July 30, 2026
Enrollment
156 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections